EUROPE'S PREMIUM CANNABIS CULTIVATOR NOVEMBER 2022 DISCLAIMER FORWARD - LOOKING STATEMENTS Various statements contained in this presentation, including those that express a belief, expectation or intention, as well a s t

EUROPE'S PREMIUM CANNABIS CULTIVATOR NOVEMBER 2022

DISCLAIMER FORWARD - LOOKING STATEMENTS Various statements contained in this presentation, including those that express a belief, expectation or intention, as well a s t hose that are not statements of historical fact, are forward - looking statements. These forward - looking statements may include projections and estimates concerning the Company's poss ible or assumed future results of operations, financial condition, business strategies and plans, market opportunity, competitive position, industry environment, and poten tia l growth opportunities. In some cases, you can identify forward - looking statements by terms such as "may", "might", "will", "should", "believe", "expect", "could", "would", "i ntend", "plan", "anticipate", "estimate", "continue", "predict", "project", "potential", "target," "goal" or other words that convey the uncertainty of future events or outcomes. You can als o i dentify forward - looking statements by discussions of strategy, plans or intentions. The Company has based these forward - looking statements on the Company's current expectations and assumptions about future events. While the Company's management considers these expectations and assumptions to be reasonable, because forward - looking statements relate to matters that have not yet occurred, they are inherently subject to significant business, competitive, economic, regulatory and other risks, contingencies and uncertai nti es, most of which are difficult to predict and many of which are beyond the Company's control. These and other important factors may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward - looking statements in this presentation, includi ng among other things: the Company's limited operating history; unpredictable events, such as the COVID - 19 outbreak, and associated business disruptions; changes in cannabis laws, regulations and guidelines; decrease in demand for cannabis and cannabis - derived products; exposure to product liability claims and actions; damage to the Company's rep utation due to negative publicity; risks associated with product recalls; the viability of the Company's product offerings; the Company's ability to attract and retai n s killed personnel; maintenance of effective quality control systems; regulatory compliance risks; risks inherent in an agricultural business; increased competition in the markets in whi ch the Company operates and intends to operate; the success of the Company's continuing research and development efforts; risks associated with expansion into new jurisdictions; ri sks related to the Company's international operations in the United Kingdom and the Kingdom of Lesotho, including the implications of the United Kingdom's recent withdr awa l from the European Union; the Company's ability to obtain and maintain adequate insurance coverage; the Company's ability to identify and integrate strategic acquisi tio ns, investments and partnerships and to manage its growth; the Company's ability to raise capital and the availability of future financing; emerging market risks; global econo my risks; and the Company's ability to maintain the listing of the Company's securities on Nasdaq. These risks and other uncertainties are described more fully in the "Risk Factors" sec tio n of the Company's most recent filings with the United States Securities and Exchange Commission and available at www.sec.gov . Given the foregoing risks and uncertainties, you are cautioned not to place undue reliance on the forward - looking statements in this presentation and the Company's filings with the United States Securities and Exchange Commiss ion. The forward - looking statements contained in this presentation and the Company's filings with the United States Securities and Exchange Commission are not guarantees o f f uture performance, and the Company's actual results of operations and financial condition may differ materially from such forward - looking statements. In addition, even if t he Company's results of operations and financial condition are consistent with the forward - looking statements in this presentation and the Company's filings with the United Stat es Securities and Exchange Commission, they may not be predictive of results or developments in future periods. Except as required by applicable law, including the securitie s l aws of the United States, the Company undertakes no obligation to publicly release any update or revision to any forward - looking statements to reflect new information, future event s or circumstances, or otherwise after the date hereof. TRADEMARKS This confidential presentation may contain trademarks, service marks, trade names and copyrights of other companies, which ar e t he property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed wi thout the TM, SM or symbols, but the Company will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, se rvi ce marks, trade names and copyrights . MARKET & INDUSTRY DATA Projections, estimates, industry data and information contained in this presentation, including the size of and growth in key en d markets, are based on information from third - party sources and management estimates. Although the Company believes that its third party - sources are reliable, the Company cannot gu arantee the accuracy or completeness of its sources. The Company's management estimates are derived from third - party sources, publicly available information, the Company's knowledge of its industry and assumptions based on such information and knowledge. The Company's management estimates have not been verified by any independent source. Al l of the projections, estimates, market data and industry information used in this presentation involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. In addition, projections, estimates and assumptions relating to the Company's and its industry's future performance are necessar ily subject to a high degree of uncertainty and risk due to a variety of factors, including, but not limited to, those described above, that could cause future performance to differ ma terially from the Company's expressed projections, estimates and assumptions or those provided by third parties 1

Premium Dried Flower Contract Manufacturing Services Distribution Services Founded: 2021 Offices: UK, Portugal, Canada Employees: 49 Ticker: NASDAQ: AKAN Key Product offerings: COMPANY PROFILE Capitalization Shares Outstanding: 30.81M Public Float: 8.91M Insider Ownership: 72.86% Market Cap (12/10/22): $7.918M Enterprise Value (12/10/22): $13.74M Company Profile & Investment Highlights 10,000kg of processing capacity available at indoor grow facility in Portugal 180 - acre outdoor and greenhouse expansion site in Portugal SCALABLE CULTIVATION AND ADVANCED PACKAGING Selling 25%+ high THC flower into Germany, the largest medical cannabis market in Europe Distribution business in United Kingdom generating revenues and ready to scale TARGETING FAST GROWING MARKETS Genetics and retail partnership with Cookies, one of the world's top cannabis brands Cookies premium g enetics received at our Portuguese facility and ready to cultivate Anticipating launch of Cookies branded flower in 2023 LEVERAGING WORLD CLASS GENETICS The only commercial scale premium indoor EU GMP certified and licensed grow in Portugal 2,000kg+ annual production, generating revenue with large German offtake agreement Clean testing non - irradiated quality flower cultivated by an experienced European team PREMIUM INDOOR CULTIVATION NASDAQ: AKAN 2 Holigen (Portugal) and Canmart (UK) subsidiaries on track to achieve operational profitability and generate positive cash flow in H1/2023 FOCUS ON PROFITABILITY

Akanda's Experienced European Leadership Team Proven leader with over 15 years of executive - level experience in the capital markets and cannabis industry, including previously serving as Managing Director, Europe, for Canopy Growth Corp A ccomplished global business leader with over 15 years of direct cannabis industry experience with an emphasis on facility design and operations, including multiple large scale EU GMP certified cultivation facilities STEVE GEORGE Commercial Director JOSH SQUIRES - QUINN Business Development SUSANA GUERRA Quality & Regulatory Director JOSE MATOS Technical Director BRUNO GANCHO Finance Director BEN JACKSON Head of Cultivation TEJ VIRK CEO & Director TOM FLOW COO NASDAQ: AKAN 3

EU GMP Packaging inhouse cultivated flower, co - packing third party sourced flower, and other contract manufacturing services ADVANCED PACKAGING Multiple routes to market with large distributors in Germany and respected telehealth partners in the UK MARKET ACCESS Committed to highest quality standards under EU GACP, utilizing proven genetics from world class partners and building our own leading library PREMIUM QUALITY CULTIVATION $2.2 BILLION European Market 1 NASDAQ: AKAN 1. Source: Prohibition Partners PRIORITIZED OPERATIONS CULTIVATION PACKAGING DISTRIBUTION World - leading EU GMP - certified cultivation facility in Portugal distributing premium medical cannabis to fast - growing markets in Europe. Akanda is Europe's Premium Cannabis Cultivator 4

Portugal is Europe's Heart of Production for Cannabis Portuguese cannabis exports increased by 566% in 2021 to 30 tonnes 1 Since legalizing medical cannabis in 2018, Portugal has become a global hub for medical cannabis production Solid reputation with extensive pharma capabilities 2021 exports reached 30 metric tonnes 1 Low production costs within Europe Barriers to entry are high, licensing process is lengthy Close to large markets like Germany and the UK Portugal adult - use legalization is progressing 5 1. Portuguese cannabis exports increased by 566 % in 2021 to 30 tons, according to information from Infarmed , Portugal's National Medical Authority . NASDAQ: AKAN

GERMANY LEADING THE WAY German Cannabis Market In Focus NASDAQ: AKAN 6 In November 2021, the incoming governing coalition reaches agreement to legalize cannabis nationwide German Imports of Cannabis Flower (KGs) 1 Population 83.2 MILLION Total Addressable Market 3 9.6 MILLION CANNABIS CONSUMERS Annual Cannabis Usage Rate 2 13.3% Annual Consumption Volume 3 1.7 MILLION KG LEGALIZATION Medical Use Adult Use Decriminalized 1. Source : The Federal Institute for Drugs and Medical Devices ( Bundesinstitut f r Arzneimittel und Medizinprodukte , BfArM ) . 2. Source : New Frontier Data 3. Prohibition Partners, European Cannabis Report : 7 th Edition . Akanda's presence in the German medical cannabis market today is building brand awareness ahead of adult u se legalization, expected by 2024 $ 2.2b Potential growth to by 2026 3 $ 354m Current market value estimation of Europe 3 $ 275m Germany remains the largest market with ~ $2 75m in sales in 2021, with 9 tonnes of medical cannabis sold into pharmacies (48% growth from 2020) 3 Akanda's premium indoor high THC flower is in demand by patients and now shipping to Germany $3 b Black market sales for estimated 3.6m consumers 3

EU GMP Premium Indoor Cultivation Purpose - built design , all unnecessary equipment sitting outside of the rooms to reduce contamination risk NASDAQ: AKAN 7 Self contained modular grow rooms, allowing for better environmental control and the production of high - quality premium cannabis No irradiation required Estimated less than 10% of LP's have this ability SINTRA FACILITY 2,000kg per year EU GMP certified One of few Licensed indoor grows in Portugal AN AKANDA COMPANY High THC, average THC value between 25 - 30%

Genetics & Brand Partnership NASDAQ: AKAN Akanda is the exclusive cultivation and retail partner for Cookies in Portugal, bringing California style cannabis to Europe Cookies, founded in 2010 by Billboard - charting rapper and entrepreneur Berner and Bay Area breeder and cultivator Jai, is the most globally recognized cannabis company in the world Cookies has taken a leading role in the development of genetics, such as Girl Scout Cookies and offers a collection of over 70 proprietary cannabis cultivars and more than 2,000 products Cookies was named one of America's Hottest Brands of 2021 by AdAge ; the first cannabis brand to ever receive this accolade Berner, Co - Founder and CEO of Cookies: "The fact Portugal decriminalized drugs back in the early 2000's and people in the U.S. are still being locked up for cannabis 20 years later, shows the world, especially the U.S., that we can learn a lot from their forward thinking. The partners we chose in Portugal have one of the most advanced facilities I've seen and will be producing some of the best cannabis in the world. It's partnerships like this that keep me excited about the growth and expansion of Cookies worldwide." Akanda to cultivate Cookies' leading strains from its EU GMP indoor grow facility in Portugal Cookies has huge brand awareness with cannabis consumers in Europe Akanda has imported Cookies genetics into Portugal Cookies to also assist Akanda with any future pharmacy distribution strategy in Portugal 8 Company Profile Early testing indicate THC % of over 25% (and some cases 30%)

Current Expansion Opportunities in Portugal ALJUSTREL, PORTUGAL SINTRA, PORTUGAL INDOOR CULTIVATION & PACKAGING 20,000 square feet indoor facility 10 Tonnes * annual production capacity of premium cannabis 7 million square feet (180+ acres) 28,000 square feet of greenhouse canopy 100 tonnes annual production capacity OUTDOOR & GREENHOUSE CULTIVATION NASDAQ: AKAN 9 AN AKANDA COMPANY *2 tonnes in house cultivated and 8 tonnes co - packing

3. Phlo digitally contacts patient for payment and delivery Akanda is Supplying the UK Medical Cannabis Market 1. Canmart imports medical cannabis to supply UK Wholesalers and Pharmacies 2. Canmart manages inventory with Phlo and Leva for next day delivery to patients + 1. Patient books appointment via App Patient Journey Product Journey 2. Virtual consultation with doctors generate digital prescriptions Repeat Rx 4. Monthly repeat prescriptions initiated by Leva app, no further consultation required 10

European Cannabis is Attractive to Smart Money Investors NASDAQ: AKAN 11 APRIL 2021 CULTIVATOR Curaleaf acquires Emmac for US$130 million in cash and shares Capacity 10 tonnes p/ year 1 SEPTEMBER 2022 DISTRIBUTOR ~$200m in strategic investments have been made into early stage European cannabis companies recently SEPTEMBER 2022 DISTRIBUTOR BAT leads Series B investment round of 37.6m in Sanity Group 5 Curaleaf agreement to acquire a 55% stake in Four 20 Pharma GmbH 4 FEBRUARY 2022 Casa Verde Leads US$15m Series B For German Distributor Cansativa Group 3 DISTRIBUTOR OCTOBER 2021 DISTRIBUTOR Bloomwell Group secures US$10 million investment. US growth capital provider Measure 8 VP is lead investor 2 1. Source :. Cision PR Newswire 2. Source : Cannabis Business Times 3. Source : Business Cann 4. Source : Cision PR Newswire 5. Source : Business Cann

THANK YOU GET IN TOUCH WITH US TEJ VIRK CEO & DIRECTOR TEJ@AKANDACORP.COM